Browsing by Author Wheeler, Helen

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 25  next >
Issue DateTitleAuthor(s)Citation
2016Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trialBack, Michael; Khasraw, Mustafa; Lee, Adrian; Wheeler, Helen; Ackland, Stephen; Buyse, Marc E.; Kerestes, Z; Kichenadasse, G; McCowatt, Sally; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; Northern Clinical School: MedicineCilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, Journal of Neuro-Oncology, vol.128, 1, 2016,pp 163-171
2016Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trialBack, Michael; Khasraw, Mustafa; Lee, Adrian; Wheeler, Helen; Ackland, Stephen; Buyse, Marc E.; Kerestes, Z; Kichenadasse, G; McCowatt, Sally; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; Northern Clinical School: MedicineCilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, Journal of Neuro-Oncology, vol.128, 1, 2016,pp 163-171
2016Divergent clonal selection dominates medulloblastoma at recurrenceWheeler, Helen; Cavalli, Florence; et al, .; Garzia, Livia; Huang, Xi; Lindsay, Patricia E.; Morrissy, A. Sorana; Ramaswamy, Vijay; Remke, Marc; Shih, David; Skowron, Patryk; Zuyderduyn, Scott; Northern Clinical School: MedicineDivergent clonal selection dominates medulloblastoma at recurrence, Nature, vol.529, 7586, 2016,pp 351-357
2014Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomideBack, Michael; Gzell, Cecelia; Wheeler, Helen; Guo, Linxin; Kastelan, M; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: MedicineElderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide, Journal of Neuro-Oncology, vol.119, 1, 2014,pp 187-196
2014Employment following chemoradiotherapy in glioblastoma: A prospective case seriesBack, Michael; Wheeler, Helen; Guo, Linxin; Gzell, Cecelia; Kastelan, M; Northern Clinical School: Medicine; Northern Clinical School: MedicineEmployment following chemoradiotherapy in glioblastoma: A prospective case series, Journal of Cancer Survivorship, vol.8, 1, 2014,pp 108-113
2013Expanding the spectrum of IDH1 mutations in gliomasBuckland, Michael; Flanagan, Simon; Gupta, Ruta; Lee, Maggie; Maleki, Sanaz; Li, Cheryl; Shivalingham, Brindha; Wheeler, Helen; School of Medical Sciences: Brain & Mind Research Institute; School of Medical Sciences: Pathology; School of Medical Sciences: Pathology; School of Medical Sciences: Pathology; Northern Clinical School: Kolling InstituteExpanding the spectrum of IDH1 mutations in gliomas, Modern Pathology, vol.26, 5, 2013,pp 619-625
2017Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastomaBarnes, Elizabeth; Espinoza, David; King, Madeleine; Sawkins, Kate; Simes, Robert John; Cher, L; Field, Kathryn; Hovey, Elizabeth; Nowak, Anna K.; Rosenthal, Mark; Wheeler, Helen; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Psychology; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma, Journal of Neuro-Oncology, vol.133, N/A, 2017,pp 623-631
2011The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centreBuckland, Michael; McDonald, Kerrie; Afaghi, Vahid; Biggs, Michael T.; Brewer, Janice M.; Cook, Raymond J.; Little, Nicholas S.; Parkinson, Jonathon F.; Payne, Cathy A.; Wheeler, Helen; School of Medical Sciences: Pathology; Northern Clinical School: Kolling InstituteThe impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre, Journal of Clinical Neuroscience, vol.18, 3, 2011,pp 329-333
2017Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyNowak, Anna; Wheeler, Helen; Baumert, Brigitta; Baurain, Jean Francais; Brandes, Alba Ariela; Clement, Paul M; Erridge, Sara C; et al, Various; Mason, Warren P; Sanson, Marc; van den Bent, M J; Vogelbaum, Michael A; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineInterim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study, The Lancet, vol.390, 10103, 2017,pp 1645-1653
2017Intertumoral Heterogeneity within Medulloblastoma SubgroupsWheeler, Helen; Cavalli, Florence; et al, Various; Garzia, Livia; Luu, Betty; Nor, Carolina; Peacock, John; Rampasek, Ladislav; Remke, Marc; Shih, David; Torchia, Jonathon; Northern Clinical School: MedicineIntertumoral Heterogeneity within Medulloblastoma Subgroups, Cancer Cell, vol.31, 6, 2017,pp 737-754
2016Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastomaChen, Jason; Cheng, Zhangkai; Dwight, Trisha; Howell, Viive; Hudson, Amanda; Ikin, Rowan; Khong, Peter; Parker, Nicole Renee; Parkinson, Jonathon; Vafaee, Fatemeh; Wheeler, Helen; Zhu, Ying; Northern Clinical School: Pathology; Physics; Northern Clinical School: NCS Office; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Mathematics & Statistics; Northern Clinical School: Medicine; Northern Clinical School: MedicineIntratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma, Scientific Reports, vol.6, N/A, 2016,pp 1-10
2015Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade gliomaBack, Michael; Gzell, Cecelia; Wheeler, Helen; Guo, Linxin; Kastelan, M; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: MedicineLarge volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma, Neuro-oncology practice, vol.2, 1, 2015,pp 48-53
2015Molecular heterogeneity in glioblastoma: potential clinical implicationsHowell, Viive; Khong, Peter; Parker, Nicole Renee; Parkinson, Jonathon; Wheeler, Helen; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Medicine; Northern Clinical School: MedicineMolecular heterogeneity in glioblastoma: potential clinical implications, Frontiers in Oncology, vol.5, N/A, 2015,pp 1-9
2010Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytomaFowler, Adam; Matar, Elie; McDonald, Kerrie; Robinson, Bruce; Biggs, Michael T.; Cook, Raymond J.; Little, Nicholas S.; Wheeler, Helen; Northern Clinical School: Kolling Institute; Physiology; Northern Clinical School: Kolling Institute; Northern Clinical School: MedicinePost-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma, Journal of Clinical Neuroscience, vol.17, 8,pp 993-996
2010Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer SurvivalHenson, Jeremy; McDonald, Kerrie; McDonnell, Julie; Reddel, Roger; Robinson, Bruce; Biggs, Michael T.; Cook, Raymond J.; Hegi, MoniKA; Little, Nicholas S.; Muntoni, Alessandra; Royds, Janice; von Deimling, Andreas; Wheeler, Helen; Children's Hospital Westmead: Childrens Medical Research Ins; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Children's Hospital Westmead: Childrens Medical Research Ins; Northern Clinical School: MedicinePresence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival, Journal of Neuropathology and Experimental Neurology, vol.69, 7,pp 729-736
2016Proliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade GliomaBack, Michael; Chen, Jason; Gzell, Cecelia; Wheeler, Helen; Gaur, P; Huang, D; Kastelan, M; Northern Clinical School: Medicine; Northern Clinical School: Pathology; Northern Clinical School: Medicine; Northern Clinical School: MedicineProliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade Glioma, Clinical Oncology, vol.28, 3, 2016,pp 215-222
2017Radiotherapy in Glioblastoma: the Past, the Present and the FutureBack, Michael; Bailey, Dale; de Gzell, Cecelia; Wheeler, Helen; Foote, Matthew; Northern Clinical School: Medicine; Medical Imaging and Radiation Sciences; Northern Clinical School: Medicine; Northern Clinical School: MedicineRadiotherapy in Glioblastoma: the Past, the Present and the Future, Clinical Oncology, vol.29, 1, 2017,pp 15-25
2015Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastomaBarnes, Elizabeth; Brown, Christopher; Livingstone (nee Ratcliffe), Ann; Sawkins, Kate; Simes, Robert John; Cher, Lawrence; Field, Kathryn; Fitt, Greg; Freilich, Ron; Hovey, Elizabeth; Nowak, Anna; Phal, Pramit M; Rosenthal, M.A.; Wheeler, Helen; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreRandomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma, Neuro-Oncology, vol.17, 11, 2015,pp 1504-1513
2017The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET)Barnes, Elizabeth; Sawkins, Kate; Simes, Robert John; Cher, Lawrence; Field, Kathryn; Fitt, G; Goh, Christine; Hovey, Elizabeth; Nowak, Anna K.; Phal, Pramit M.; Rosenthal, Mark; Wheeler, Helen; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreThe role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET), Cancer, vol.123, 18, 2017,pp 3576-3582
2011Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-upMcDonald, Kerrie; Biggs, Michael T.; Cook, Raymond J.; Fowler, A; Gonzalvo, Augusto; Little, Nicholas S.; Wheeler, Helen; Northern Clinical School: Kolling InstituteSchwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up, Journal of Neurosurgery, vol.114, 3, 2011,pp 756-762